NEW YORK (GenomeWeb) – NIPD Genetics of Cyprus has been advancing research into epigenetic markers to distinguish fetal from maternal DNA, which may eventually lead to new clinical tests for prenatal screening, cancer diagnostics, and other applications. In parallel, the company has been expanding sales and applications for its current Veracity noninvasive prenatal test and plans to offer microdeletion testing next year.
NIPD Genetics Pursues Potential of Methylation Markers for Prenatal Testing, Other Applications
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.